Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen

Chen-Te Huang, Tai-Chung Tseng

Clin Mol Hepatol. 2024;30(2):154-156. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0120

View: 1895 Download: 58 Crossref: 1

Original Article

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um

Clin Mol Hepatol. 2016;22(3):382-389. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0047

View: 12521 Download: 201 Web of Science: 18 Crossref: 19

3

Efficacy of Lamivudine Re-treatment and Relapse Patterns after Initial Lamivudine Treatment for Chronic Hepatitis B Infection

Jong Ho Park, M.D., Neung Hwa Park, M.D., Jung Woo Shin, M.D., Sung-Jo Bang, M.D., Dae-Hyun Kim, M.D., Kwang Ro Joo, M.D. and Do Ha Kim, M.D.

Clin Mol Hepatol. 2003;9(3):188-197. Published online January 1, 1970

View: 2568 Download: 13

Efficacy of Lamivudine in Patients with Hepatitis B e Antigen-Negative Chronic Liver Diseases

In Du Jeong , Neung Hwa Park , Byung Chul Kim , Jee Hyun Park , Kwang Won Seo , Dae Hyun Kim , Kwang Ro Joo , Do Ha Kim

Clin Mol Hepatol. 2003;9(2):69-78. Published online January 1, 1970

View: 2856 Download: 11

The Effect of Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B Virus Infection

Neung Hwa Park,Kwang Ro Joo,Do Ha Kim

Clin Mol Hepatol. 2001;7(1):77-89. Published online January 1, 2000

View: 2543 Download: 20

1 |

Viewed By 4934	MAFLD: How is it different from NAFLD?
Viewed By 4828	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4728	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4446	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4403	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 95	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search